280 related articles for article (PubMed ID: 37459511)
1. IL-7R licenses a population of epigenetically poised memory CD8
Micevic G; Daniels A; Flem-Karlsen K; Park K; Talty R; McGeary M; Mirza H; Blackburn HN; Sefik E; Cheung JF; Hornick NI; Aizenbud L; Joshi NS; Kluger H; Iwasaki A; Bosenberg MW; Flavell RA
Proc Natl Acad Sci U S A; 2023 Jul; 120(30):e2304319120. PubMed ID: 37459511
[TBL] [Abstract][Full Text] [Related]
2. Signaling thresholds govern heterogeneity in IL-7-receptor-mediated responses of naïve CD8(+) T cells.
Palmer MJ; Mahajan VS; Chen J; Irvine DJ; Lauffenburger DA
Immunol Cell Biol; 2011 Jul; 89(5):581-94. PubMed ID: 21339767
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
Elife; 2023 Jan; 12():. PubMed ID: 36705564
[TBL] [Abstract][Full Text] [Related]
4. Non-redundant role for IL-7R signaling for the survival of CD8+ memory T cells.
Carrio R; Rolle CE; Malek TR
Eur J Immunol; 2007 Nov; 37(11):3078-88. PubMed ID: 17935075
[TBL] [Abstract][Full Text] [Related]
5. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
6. Prosurvival IL-7-Stimulated Weak Strength of mTORC1-S6K Controls T Cell Memory via Transcriptional FOXO1-TCF1-Id3 and Metabolic AMPKα1-ULK1-ATG7 Pathways.
Xu A; Leary SC; Islam MF; Wu Z; Bhanumathy KK; Ara A; Chibbar R; Fleywald A; Ahmed KA; Xiang J
J Immunol; 2022 Jan; 208(1):155-168. PubMed ID: 34872976
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
[TBL] [Abstract][Full Text] [Related]
8. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.
Tietze JK; Wilkins DE; Sckisel GD; Bouchlaka MN; Alderson KL; Weiss JM; Ames E; Bruhn KW; Craft N; Wiltrout RH; Longo DL; Lanier LL; Blazar BR; Redelman D; Murphy WJ
Blood; 2012 Mar; 119(13):3073-83. PubMed ID: 22251483
[TBL] [Abstract][Full Text] [Related]
9. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
10. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
[TBL] [Abstract][Full Text] [Related]
11. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.
Chapuis AG; Thompson JA; Margolin KA; Rodmyre R; Lai IP; Dowdy K; Farrar EA; Bhatia S; Sabath DE; Cao J; Li Y; Yee C
Proc Natl Acad Sci U S A; 2012 Mar; 109(12):4592-7. PubMed ID: 22393002
[TBL] [Abstract][Full Text] [Related]
12. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
13. The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells.
Lozza L; Rivino L; Guarda G; Jarrossay D; Rinaldi A; Bertoni F; Sallusto F; Lanzavecchia A; Geginat J
Eur J Immunol; 2008 Jan; 38(1):30-9. PubMed ID: 18081042
[TBL] [Abstract][Full Text] [Related]
14. Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients.
Rosenthal R; Groeper C; Bracci L; Adamina M; Feder-Mengus C; Zajac P; Iezzi G; Bolli M; Weber WP; Frey DM; von Holzen U; Oertli D; Heberer M; Spagnoli GC
J Immunother; 2009 Apr; 32(3):252-61. PubMed ID: 19242375
[TBL] [Abstract][Full Text] [Related]
15. Loss of IL-7R and IL-15R expression is associated with disappearance of memory T cells in respiratory tract following influenza infection.
Shen CH; Ge Q; Talay O; Eisen HN; García-Sastre A; Chen J
J Immunol; 2008 Jan; 180(1):171-8. PubMed ID: 18097017
[TBL] [Abstract][Full Text] [Related]
16. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.
Kaech SM; Tan JT; Wherry EJ; Konieczny BT; Surh CD; Ahmed R
Nat Immunol; 2003 Dec; 4(12):1191-8. PubMed ID: 14625547
[TBL] [Abstract][Full Text] [Related]
17. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
18. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
19. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology.
Lin GH; Snell LM; Wortzman ME; Clouthier DL; Watts TH
J Immunol; 2013 May; 190(9):4627-39. PubMed ID: 23536631
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
